The Advisory Board (NASDAQ: ABCO) recently received a number of ratings updates from brokerages and research firms:

  • 9/1/2017 – The Advisory Board had its “hold” rating reaffirmed by analysts at KeyCorp.
  • 8/29/2017 – The Advisory Board was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $54.00 price target on the stock, down previously from $63.00.
  • 8/29/2017 – The Advisory Board was downgraded by analysts at William Blair from an “outperform” rating to a “hold” rating.
  • 8/29/2017 – The Advisory Board was downgraded by analysts at Canaccord Genuity from a “buy” rating to a “hold” rating. They now have a $54.29 price target on the stock, down previously from $56.00.
  • 8/29/2017 – The Advisory Board had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $54.00 price target on the stock, up previously from $45.00.
  • 8/10/2017 – The Advisory Board was given a new $51.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 8/10/2017 – The Advisory Board had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $56.00 price target on the stock, up previously from $53.00.
  • 8/5/2017 – The Advisory Board was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/25/2017 – The Advisory Board was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “The Advisory Board Company provides best practices research and analysis to the health care industry, focusing on business strategy, operations and general management issues. The Company provides its best practices research and analysis through discrete annual programs to a membership of more than 2,000 hospitals, health systems, pharmaceutical and biotech companies, health care insurers, and medical device companies in the United States. Each program provides members with best practices research reports, executive education and other supporting research services. “
  • 7/9/2017 – The Advisory Board had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $65.00 price target on the stock, up previously from $57.00.

Shares of The Advisory Board Company (NASDAQ:ABCO) remained flat at $53.35 during mid-day trading on Thursday. The company had a trading volume of 930,143 shares. The company has a market capitalization of $2.17 billion, a PE ratio of 20.26 and a beta of 1.35. The Advisory Board Company has a 52-week low of $24.85 and a 52-week high of $59.50. The firm has a 50-day moving average of $53.52 and a 200-day moving average of $50.47.

The Advisory Board (NASDAQ:ABCO) last announced its earnings results on Tuesday, August 8th. The business services provider reported $0.24 EPS for the quarter, missing the Zacks’ consensus estimate of $0.32 by $0.08. The company had revenue of $200.30 million during the quarter, compared to analysts’ expectations of $196.16 million. The Advisory Board had a return on equity of 12.69% and a net margin of 13.65%. The Advisory Board’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.46 EPS. On average, analysts anticipate that The Advisory Board Company will post $1.90 earnings per share for the current year.

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company offers subscription-based membership programs, software and data-enabled services. All of its programs are rooted in best practices and extends across four areas, including Best practices research, Technology, Data-enabled services and Consulting services.

Receive News & Ratings for The Advisory Board Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Company and related companies with MarketBeat.com's FREE daily email newsletter.